Adjunctive treatments for type 1 diabetes

New England Journal of Medicine

Volumn 377, Issue 24, 2017, Pages 2390-2391

  Nathan, David M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANAGLIFLOZIN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLYCOSYLATED HEMOGLOBIN; INSULIN; METFORMIN; PRAMLINTIDE; SOTAGLIFLOZIN; ANTIDIABETIC AGENT;

BLOOD GLUCOSE MONITORING; EDITORIAL; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; KETOACIDOSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR; STOMACH EMPTYING; NON INSULIN DEPENDENT DIABETES MELLITUS;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 85038237246     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1711296     Document Type: Editorial

References (10)

1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
2. Guidance for industry: diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Silver Spring, MD: Food and Drug Administration, December 2008 (http://www .fda .gov/downloads/drugs/guidancecompliance regulatoryinformation/guidances/ucm071627 .pdf).
3. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117-28.
4. Nathan DM, Bayless M, Cleary P, et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 years: advances and contributions. Diabetes 2013; 62: 3976-86.
5. Petrie JR, Chaturvedi N, Ford I, et al. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2017; 5: 597-609.
6. Dejgaard TF, Frandsen CS, Hansen TS, et al. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2016; 4: 221-32.
7. Herrmann K, Brunell SC, Li Y, Zhou M, Maggs DG. Impact of disease duration on the effects of pramlintide in type 1 diabetes: a post hoc analysis of three clinical trials. Adv Ther 2016; 33: 848-61.
8. Garg SK, Henry RR, Banks P, et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med 2017; 377: 2337-48.
9. Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN. Effect of glycemic exposure on the risk of microvascular complications in the Diabetes Control and Complications Trial-revisited. Diabetes 2008; 57: 995-1001.
10. Henry RR, Thakkar P, Tong C, Polidori D, Alba M. Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. Diabetes Care 2015; 38: 2258-65.